| You are here: Home: BCU 9|2004: Gabriel N Hortobagyi, MD: Select publications
Select publications
Baum M et al; The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists’ Group. Anastrozole
alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of
postmenopausal women with early breast cancer: First results of the ATAC randomised trial. The
Lancet 2002;359(9324):2131-9. Erratum in: The Lancet 2002;360(9344):1520. Abstract
Baum M et al; The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists’ Group. Anastrozole
alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of
postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen
Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98(9):1802-10.
Abstract
Boccardo F et al. Anastrozole appears to be superior to tamoxifen in women already receiving
adjuvant tamoxifen treatment. Breast Cancer Res Treat 2003;82(Suppl 1):3;Abstract 3.
Buzdar AU et al. Significantly higher pathological complete remission (PCR) rate following
neoadjuvant therapy with trastuzumab (H), paclitaxel (P), and anthracycline-containing chemotherapy
(CT): Initial results of a randomized trial in operable breast cancer (BC) with HER/2
positive disease. J Clin Oncol 2004;22(14 Suppl);Abstract 520.
Coombes RC et al. A randomized trial of exemestane after two to three years of tamoxifen therapy
in postmenopausal women with primary breast cancer. N Engl J Med 2004;350(11):1081-92.
Abstract
Goss PE et al. A randomized trial of letrozole in postmenopausal women after five years of
tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349(19):1793-802. Abstract
Hortobagyi GN. What is the prognosis of patients with operable breast cancer (BC) five years after
diagnosis? J Clin Oncol 2004;22(14 Suppl);Abstract 585.
Jones SE et al. Randomized trial comparing docetaxel and paclitaxel in patients with metastatic
breast cancer. Breast Cancer Res Treat 2003;82(Suppl 1):9;Abstract 10.
Robertson JF et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma
in postmenopausal women: A prospective combined analysis of two multicenter trials. Cancer 2003;98(2):229-38. Abstract
Venturini M et al. Phase III adjuvant trial comparing standard versus accelerated FEC regimen
in early breast cancer patients. Results from GONO MIG1 study. Breast Cancer Res Treat 2003;Abstract 12.
|
